The Fly | CGON

CG Oncology, Inc.

· CGON

Dashboard

Financials

Ratios

Valuation

Yesterday

Closing Bell Movers: Micron soars 14% after beat and raise

+14

Yesterday, 7:48 PM

CG Oncology 1.15M share Block Trade; price range $66.87-$67.87

CGON

Yesterday, 5:40 PM

Over a week ago

Oncolytics promotes John McAdory to COO

Jun 2, 9:22 AM

Wolfe sees CG Oncology COO exit as operational, no impact to key programs

CGON

May 26, 11:36 AM

CG Oncology announces departure of president, COO Ambaw Bellete

CGON

May 26, 11:33 AM

CG Oncology initiated with neutral view at Wolfe Research, here's why

CGON

May 19, 6:07 AM

CG Oncology reports first results from CORE-008 Cohort CX

CGON

May 15, 8:18 AM

CG Oncology price target raised by $5 at Truist, here's why

CGON

May 14, 9:18 AM

CG Oncology price target raised by $2 at RBC Capital, here's why

CGON

May 11, 9:29 AM

CG Oncology price target raised by $5 at JPMorgan

CGON

May 11, 9:12 AM

CG Oncology price target raised by $3 at Wedbush, here's why

CGON

May 11, 7:50 AM

CG Oncology price target lowered by $1 at BofA, here's why

CGON

May 10, 10:26 AM

CG Oncology reports Q1 EPS (71c), consensus (54c)

CGON

May 8, 8:37 AM

CG Oncology price target raised by $6 at RBC Capital, here's why

CGON

Apr 27, 8:09 AM

Biotech Alert: Searches spiking for these stocks today

Apr 20, 12:37 PM

JPMorgan ups CG Oncology target, adds 'Positive Catalyst Watch'

Apr 17, 7:05 AM

CG Oncology price target raised by $12 at BofA, here's why

CGON

Apr 14, 7:47 AM

JPMorgan healthcare analysts hold an analyst/industry conference call

Apr 9, 11:36 AM

CG Oncology price target raised by $20 at H.C. Wainwright, here's why

CGON

Apr 7, 5:51 AM

CG Oncology price target raised by $30 at UBS, here's why

CGON

Mar 26, 9:03 AM

CG Oncology price target raised by $7 at BofA, here's why

Mar 13, 3:31 PM

CG Oncology price target raised by $5 at H.C. Wainwright, here's why

CGON

Feb 27, 12:19 PM

CG Oncology sees cash runway into 1H29

CGON

Feb 27, 8:35 AM

CG Oncology reports FY25 EPS ($2.08), consensus (58c)

CGON

Feb 27, 8:34 AM

Approved Lead Product: CRESTOR (nadofaragene firadenovec) is the first and only FDA-approved gene therapy for high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), providing immediate market access and revenue generation.

Addressing High Unmet Need: Targets a critical patient population with high-risk NMIBC that is unresponsive to Bacillus Calmette-Guérin (BCG) therapy, a segment with limited effective treatment options.

Novel Mechanism of Action: Utilizes an innovative intravesical gene therapy approach delivering an adenovirus vector to stimulate a robust immune response against cancer cells, offering a differentiated therapeutic strategy.

Clinical Trial Outcomes Risk: The success of CG Oncology's lead product candidate, cretostimogene, is highly uncertain, and future clinical trials may not achieve their primary endpoints, leading to significant delays or failure to obtain regulatory approval.

Regulatory Approval Risk: Even with positive clinical data, CG Oncology may fail to obtain necessary regulatory approvals from the FDA or other global health authorities for its product candidates, or approvals may be significantly delayed.

Commercialization and Market Adoption Risk: If approved, CG Oncology's product candidates may not achieve market acceptance or gain significant market share due to competition, unfavorable pricing, or lack of physician and patient adoption.